Press release
Neurofibromatosis Type 2 Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, Shanghai Kechow Pharma
To Know in detail about the Neurofibromatosis Type 2 market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Type 2 Market Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Neurofibromatosis Type 2 Market Report:
• The Neurofibromatosis Type 2 market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• Based on DelveInsight's epidemiology model, there were about 10.6 thousand diagnosed prevalent cases of Neurofibromatosis Type 2 in the US in 2023. This figure is expected to increase during the forecast period (2024-2034) due to heightened awareness, improved screening, and an aging population.
• In the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of Neurofibromatosis Type 2, with around 1,359 cases in 2023. This was followed by the UK with approximately 1,185 cases and France with nearly 1,139 cases.
• In the US in 2023, among the age-specific diagnosed prevalent cases of Neurofibromatosis Type 2, adults had the highest number, totaling around 8,897 cases, while children and adolescents accounted for nearly 1,695 cases.
• In 2023, Japan had 813 diagnosed prevalent cases of Neurofibromatosis Type 2 among the 7MM.
• In 2023, the tumor-specific categories comprised Vestibular Schwannoma (CN8-NST), Trigeminal Schwannomas (CN5-NST), intracranial meningioma, and spinal nerve sheath tumors. Notably, Vestibular Schwannoma (CN8-NST) had the highest prevalence in Japan, with approximately 708 reported cases.
• Key Neurofibromatosis Type 2 Companies: Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics, AstraZeneca, Fosun Pharmaceutical, NFlection Therapeutics, Inc., and others
• Key Neurofibromatosis Type 2 Therapies: REC-2282, VT3989, HLX-1502, Mirdametinib (PD-0325901), Selumetinib, FCN-159, NFX-179 Gel, and others
• The Neurofibromatosis Type 2 market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neurofibromatosis Type 2 pipeline products will significantly revolutionize the Neurofibromatosis Type 2 market dynamics.
Neurofibromatosis Type 2 Overview
Neurofibromatosis Type 2 (NF2) is a genetic disorder characterized by the development of noncancerous tumors called schwannomas, primarily affecting the nerves. It is caused by mutations in the NF2 gene, located on chromosome 22, which plays a crucial role in the production of a protein called merlin that helps regulate cell growth.
Get a Free sample for the Neurofibromatosis Type 2 Market Report:
https://www.delveinsight.com/report-store/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Neurofibromatosis Type 2 Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Neurofibromatosis Type 2 Epidemiology Segmentation:
The Neurofibromatosis Type 2 market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Neurofibromatosis Type 2
• Prevalent Cases of Neurofibromatosis Type 2 by severity
• Gender-specific Prevalence of Neurofibromatosis Type 2
• Diagnosed Cases of Episodic and Chronic Neurofibromatosis Type 2
Download the report to understand which factors are driving Neurofibromatosis Type 2 epidemiology trends @ Neurofibromatosis Type 2 Epidemiology Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Neurofibromatosis Type 2 Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neurofibromatosis Type 2 market or expected to get launched during the study period. The analysis covers Neurofibromatosis Type 2 market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neurofibromatosis Type 2 Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Neurofibromatosis Type 2 Therapies and Key Companies
• REC-2282: Recursion Pharmaceuticals
• VT3989: Vivace Therapeutics
• HLX-1502: Healx Limited
• Mirdametinib (PD-0325901): SpringWorks Therapeutics
• Selumetinib: AstraZeneca
• FCN-159: Fosun Pharmaceutical
• NFX-179 Gel: NFlection Therapeutics, Inc.
Discover more about therapies set to grab major Neurofibromatosis Type 2 market share @ Neurofibromatosis Type 2 Treatment Market
https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Scope of the Neurofibromatosis Type 2 Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neurofibromatosis Type 2 Companies: Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, SpringWorks Therapeutics, AstraZeneca, Fosun Pharmaceutical, NFlection Therapeutics, Inc., and others
• Key Neurofibromatosis Type 2 Therapies: REC-2282, VT3989, HLX-1502, Mirdametinib (PD-0325901), Selumetinib, FCN-159, NFX-179 Gel, and others
• Neurofibromatosis Type 2 Therapeutic Assessment: Neurofibromatosis Type 2 current marketed and Neurofibromatosis Type 2 emerging therapies
• Neurofibromatosis Type 2 Market Dynamics: Neurofibromatosis Type 2 market drivers and Neurofibromatosis Type 2 market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neurofibromatosis Type 2 Unmet Needs, KOL's views, Analyst's views, Neurofibromatosis Type 2 Market Access and Reimbursement
To know more about Neurofibromatosis Type 2 companies working in the treatment market, visit @ Neurofibromatosis Type 2 Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Neurofibromatosis Type 2 Market Report Introduction
2. Executive Summary for Neurofibromatosis Type 2
3. SWOT analysis of Neurofibromatosis Type 2
4. Neurofibromatosis Type 2 Patient Share (%) Overview at a Glance
5. Neurofibromatosis Type 2 Market Overview at a Glance
6. Neurofibromatosis Type 2 Disease Background and Overview
7. Neurofibromatosis Type 2 Epidemiology and Patient Population
8. Country-Specific Patient Population of Neurofibromatosis Type 2
9. Neurofibromatosis Type 2 Current Treatment and Medical Practices
10. Neurofibromatosis Type 2 Unmet Needs
11. Neurofibromatosis Type 2 Emerging Therapies
12. Neurofibromatosis Type 2 Market Outlook
13. Country-Wise Neurofibromatosis Type 2 Market Analysis (2020-2034)
14. Neurofibromatosis Type 2 Market Access and Reimbursement of Therapies
15. Neurofibromatosis Type 2 Market Drivers
16. Neurofibromatosis Type 2 Market Barriers
17. Neurofibromatosis Type 2 Appendix
18. Neurofibromatosis Type 2 Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Neurofibromatosis Type 2 Pipeline https://www.delveinsight.com/report-store/neurofibromatosis-2-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Neurofibromatosis Type 2 Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neurofibromatosis Type 2 market. A detailed picture of the Neurofibromatosis Type 2 pipeline landscape is provided, which includes the disease overview and Neurofibromatosis Type 2 treatment guidelines.
Neurofibromatosis Type 2 Epidemiology https://www.delveinsight.com/report-store/neurofibromatosis-2-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neurofibromatosis Type 2 Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neurofibromatosis Type 2 epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
DelveInsight's 'Resorbable Vascular Scaffolds - Market Insight, Competitive Landscape, and Market Forecast - 2030' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.
Substance Drug Abuse Market
https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Trastuzuma Biosimilar
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight
DelveInsight's, "Trastuzumab Biosimilar Insight, 2024" report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Undifferentiated Pleomorphic Sarcoma Market
https://www.delveinsight.com/report-store/undifferentiated-pleomorphic-sarcoma-market
DelveInsight's "Undifferentiated Pleomorphic Sarcoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Undifferentiated Pleomorphic Sarcoma, historical and forecasted epidemiology as well as the Undifferentiated Pleomorphic Sarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Type 2 Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Fosun Pharmaceutical, SpringWorks Therapeutics, NFlection Therapeutics, Inc., AstraZeneca, Shanghai Kechow Pharma here
News-ID: 3703039 • Views: …
More Releases from DelveIinsight Business Research
Advanced Renal Cell Carcinoma Market Report 2034: Epidemiology Data, Therapies, …
DelveInsight's "Advanced Renal Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Antibody Drug Conjugates, historical and forecasted epidemiology as well as the Antibody Drug Conjugates market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Advanced Renal Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Advanced Renal…
PCSK9 Inhibitors Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, PCSK9 Inhibitors pipeline constitutes 14+ key companies continuously working towards developing 14+ PCSK9 Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"PCSK9 Inhibitors Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the PCSK9 Inhibitors Market.
The PCSK9…
Metastatic Prostate Cancer Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Metastatic Prostate Cancer pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Prostate Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Metastatic Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Prostate…
Bunion (Hallux Valgus) Market to Expand Significantly by 2034, States DelveInsig …
DelveInsight's "Bunion Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Bunion, historical and forecasted epidemiology as well as the Bunion market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Bunion market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bunion Market Forecast
https://www.delveinsight.com/sample-request/hallux-valgus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Bunion…
More Releases for Neurofibromatosis
Neurofibromatosis Market Dynamics Indicate Upward Trajectory Through 2032, Repor …
DelveInsight's "Neurofibromatosis Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Neurofibromatosis, historical and forecasted epidemiology as well as the Neurofibromatosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Neurofibromatosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neurofibromatosis Market Forecast
https://www.delveinsight.com/sample-request/neurofibromatosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Neurofibromatosis…
Neurofibromatosis Type-1 Market Is Booming Worldwide - AstraZeneca, GlaxoSmithKl …
Neurofibromatosis Type-1 Market Insights
The Neurofibromatosis Type-1 Market is projected to reach USD 2.4 billion by 2032, growing at a CAGR of 7.2% during the forecast period (2025-2032).
Coherent Market Insights has published a new comprehensive analysis on the Neurofibromatosis Type-1 Market (2025-2032), focusing on critical transformations in the U.S. healthcare environment. This report highlights essential metrics including market size, revenue forecasts, CAGR, adoption trends, and regulatory drivers. Backed by clinical evidence…
Neurofibromatosis Treatment Market Size, Industry And Forecast To 2033
The new report published by The Business Research Company, titled Neurofibromatosis Treatment Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $11.41 billion in 2023…
Neurofibromatosis Treatment Market Research Analysis, Application And Forecast T …
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Neurofibromatosis Treatment Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $21.58 billion In 2028 At…
Neurofibromatosis Type-2 Market Insight, Epidemiology and Market Forecast - 2027
Neurofibromatosis Type-2 Market research report is the new statistical data source added by Infinity Business Insights.
The genetic disease neurofibromatosis type 2 (NF2) is most often linked with bilateral vestibular schwannomas, also known as auditory neuromas. These benign (noncancerous) tumours develop on the balance and hearing nerves that go to the inner ear. Although benign, these tumours can cause hearing and balance issues. People with NF2 are also more likely…
Neurofibromatosis Treatment Market to Set Phenomenal Growth by 2023
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous…
